PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Pacific Biosciences of California, Inc. (PACB)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US69404D1081

CUSIP

69404D108

Sector

Healthcare

IPO Date

Oct 27, 2010

Highlights

Market Cap

$471.05M

EPS (TTM)

-$1.46

PEG Ratio

-0.17

Total Revenue (TTM)

$173.15M

Gross Profit (TTM)

$31.38M

EBITDA (TTM)

-$338.64M

Year Range

$1.16 - $10.65

Target Price

$3.07

Short %

21.30%

Short Ratio

6.88

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons:
PACB vs. ARDX PACB vs. ILMN PACB vs. SPY PACB vs. CRSP PACB vs. EDIT PACB vs. SQQQ
Popular comparisons:
PACB vs. ARDX PACB vs. ILMN PACB vs. SPY PACB vs. CRSP PACB vs. EDIT PACB vs. SQQQ

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Pacific Biosciences of California, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-40.00%-20.00%0.00%20.00%40.00%JuneJulyAugustSeptemberOctoberNovember
-11.36%
12.33%
PACB (Pacific Biosciences of California, Inc.)
Benchmark (^GSPC)

Returns By Period

Pacific Biosciences of California, Inc. had a return of -82.47% year-to-date (YTD) and -79.23% in the last 12 months. Over the past 10 years, Pacific Biosciences of California, Inc. had an annualized return of -12.93%, while the S&P 500 had an annualized return of 11.16%, indicating that Pacific Biosciences of California, Inc. did not perform as well as the benchmark.


PACB

YTD

-82.47%

1M

-6.52%

6M

-7.03%

1Y

-79.23%

5Y (annualized)

-19.81%

10Y (annualized)

-12.93%

^GSPC (Benchmark)

YTD

24.72%

1M

1.67%

6M

12.93%

1Y

30.55%

5Y (annualized)

13.88%

10Y (annualized)

11.16%

Monthly Returns

The table below presents the monthly returns of PACB, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024-33.64%-15.05%-32.19%-56.00%8.48%-23.46%50.36%-33.50%24.09%27.65%-82.47%
202335.57%-18.12%27.53%-8.46%16.79%7.43%-0.68%-14.61%-25.98%-25.99%37.22%15.68%19.93%
2022-45.36%6.62%-23.66%-30.33%-11.20%-21.49%-1.13%34.10%-0.85%45.27%27.37%-23.91%-60.02%
202124.71%-5.50%8.96%-10.39%-9.38%29.28%-8.06%-2.61%-18.40%3.64%-12.35%-11.85%-21.13%
2020-9.14%-27.19%-10.00%8.17%6.34%-1.99%8.12%76.94%49.55%32.83%20.59%64.07%404.67%
2019-6.49%5.64%-1.09%2.21%-9.34%-9.70%-10.74%2.78%-7.03%-6.20%6.20%0.00%-30.54%
20187.58%-16.20%-13.87%25.85%-1.94%40.32%7.04%31.32%8.42%-17.74%75.73%-5.37%180.30%
201726.84%4.77%2.38%-23.79%-16.24%7.88%-8.43%51.84%6.06%-19.43%-24.59%-17.24%-30.53%
2016-18.58%-22.45%2.53%13.53%-0.10%-26.97%21.45%-2.57%7.56%-5.13%-10.47%-50.07%-71.06%
20152.55%-21.64%-7.30%-11.64%9.30%2.13%-1.22%-12.48%-26.51%93.99%44.08%28.35%67.47%
201437.28%-7.24%-19.67%-17.38%12.22%24.60%-26.05%28.23%-16.21%33.60%3.05%15.98%49.90%
201345.88%-7.26%8.26%2.81%3.52%-4.53%2.37%61.39%32.06%-25.54%2.68%23.93%207.65%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of PACB is 11, indicating that it is in the bottom 11% of stocks on our website in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.


The Risk-Adjusted Performance Rank of PACB is 1111
Combined Rank
The Sharpe Ratio Rank of PACB is 1111
Sharpe Ratio Rank
The Sortino Ratio Rank of PACB is 1010
Sortino Ratio Rank
The Omega Ratio Rank of PACB is 1111
Omega Ratio Rank
The Calmar Ratio Rank of PACB is 44
Calmar Ratio Rank
The Martin Ratio Rank of PACB is 1717
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Pacific Biosciences of California, Inc. (PACB) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


Sharpe ratio
The chart of Sharpe ratio for PACB, currently valued at -0.68, compared to the broader market-4.00-2.000.002.004.00-0.682.54
The chart of Sortino ratio for PACB, currently valued at -1.02, compared to the broader market-4.00-2.000.002.004.00-1.023.40
The chart of Omega ratio for PACB, currently valued at 0.87, compared to the broader market0.501.001.502.000.871.47
The chart of Calmar ratio for PACB, currently valued at -0.82, compared to the broader market0.002.004.006.00-0.823.66
The chart of Martin ratio for PACB, currently valued at -1.14, compared to the broader market-10.000.0010.0020.0030.00-1.1416.26
PACB
^GSPC

The current Pacific Biosciences of California, Inc. Sharpe ratio is -0.68. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Pacific Biosciences of California, Inc. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.

Rolling 12-month Sharpe Ratio-1.000.001.002.003.00JuneJulyAugustSeptemberOctoberNovember
-0.68
2.46
PACB (Pacific Biosciences of California, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Pacific Biosciences of California, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%JuneJulyAugustSeptemberOctoberNovember
-96.64%
-1.40%
PACB (Pacific Biosciences of California, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Pacific Biosciences of California, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Pacific Biosciences of California, Inc. was 97.65%, occurring on Jul 1, 2024. The portfolio has not yet recovered.

The current Pacific Biosciences of California, Inc. drawdown is 96.64%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-97.65%Feb 12, 2021850Jul 1, 2024
-93.52%Oct 29, 2010514Nov 13, 20122026Dec 1, 20202540
-22.74%Jan 20, 20216Jan 27, 202110Feb 10, 202116
-11.19%Dec 9, 20207Dec 17, 20202Dec 21, 20209
-10.95%Dec 24, 20203Dec 29, 20206Jan 7, 20219

Volatility

Volatility Chart

The current Pacific Biosciences of California, Inc. volatility is 33.75%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%50.00%JuneJulyAugustSeptemberOctoberNovember
33.75%
4.07%
PACB (Pacific Biosciences of California, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Pacific Biosciences of California, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Pacific Biosciences of California, Inc..


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items